Topical Antifungal Treatment for Tinea Pedis
- Registration Number
- NCT01396811
- Lead Sponsor
- Medicis Global Service Corporation
- Brief Summary
The purpose of this study is to determine if a topical antifungal cream is safe and effective for the treatment of tinea pedis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 322
Inclusion Criteria
- Moderate erythema, moderate scaling, and mild pruritus
Exclusion Criteria
- Pregnancy and allergies
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Product 33525 Placebo Active 33525 Product 33525
- Primary Outcome Measures
Name Time Method Proportion of patients achieving complete clearance Day 42 Signs and Symptoms Severity Score and negative Potassium Hydroxide (KOH) and Culture
- Secondary Outcome Measures
Name Time Method Proportion of patients achieving effective treatment Day 42 Clinical Cure and Mycologic Cure
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the antifungal activity of 33525 in NCT01396811 tinea pedis trials?
How does 33525 compare to standard-of-care topical antifungals like terbinafine in treating tinea pedis?
Are there biomarkers associated with response to 33525 in dermatophyte infections such as tinea pedis?
What adverse events were reported in Medicis NCT01396811 Phase 3 tinea pedis trial and how were they managed?
What are the competitive antifungal agents or combination therapies for tinea pedis evaluated alongside 33525 in Phase 3 studies?